Mikrobiologische und klinische Erfahrungen mit Cefoxitin View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1979-01

AUTHORS

W. Graninger, S. Breyer, H. Pichler

ABSTRACT

Two hundred and ninety-two clinical isolates resistant to cephalothin were tested against cefamandole, cefoxitin, cefuroxime and HR 756 by the standardized agar diffusion technique. Compared to other cephalosporins tested, cefoxitin was highly active against indolpositiveProteus spp. andSerratia marcescens. Cefuroxime showed good activity againstEscherichia coli, Proteus mirabilis andEnterobacter. Cefamandole, the weakest of the compounds tested, was more active than cefoxitin only againstE. coli HR 756 proved to be the most effective cephalosporin derivative in vitro; it exhibited antibacterial activity againstStreptococcus faecalis andPseudomonas aeruginosa. All compounds showed equally high activity againstStaphylococcus aureus. Sixteen patients with chronic infections of the upper urinary tract (8), osteomyelitis (4), soft tissue infections (3) and pneumonia (1) were treated with cefoxitin administered intravenously in dosages ranging from 3 g/die (urinary tract infections) to 12 g/die (soft tissue infections) for a period of 2–4 weeks. With the exception of two cases the infection was eliminated with cefoxitin. One patient developed a superinfection withP. aeruginosa. One patient with purulent coxitis caused byProvidencia andPseudomonas aeruginosa did not respond to cefoxitin in a daily dose of 12 g. Side-effects observed consisted of allergic exanthema in one patient, and headache and dizziness after rapid intravenous infusion in another patient. No signs of hematological or nephrological toxicity were observed. Local tolerance was good. More... »

PAGES

s99-s102

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01639474

DOI

http://dx.doi.org/10.1007/bf01639474

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046693138


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graninger", 
        "givenName": "W.", 
        "id": "sg:person.013723243562.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013723243562.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Breyer", 
        "givenName": "S.", 
        "id": "sg:person.014412360064.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014412360064.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Universit\u00e4tsklinik f\u00fcr Chemotherapie, Lazarettgasse 14, A-1090, Wien, \u00f6sterreich"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pichler", 
        "givenName": "H.", 
        "id": "sg:person.016047012041.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016047012041.22"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01640793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033338319", 
          "https://doi.org/10.1007/bf01640793"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01639103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030419629", 
          "https://doi.org/10.1007/bf01639103"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1979-01", 
    "datePublishedReg": "1979-01-01", 
    "description": "Two hundred and ninety-two clinical isolates resistant to cephalothin were tested against cefamandole, cefoxitin, cefuroxime and HR 756 by the standardized agar diffusion technique. Compared to other cephalosporins tested, cefoxitin was highly active against indolpositiveProteus spp. andSerratia marcescens. Cefuroxime showed good activity againstEscherichia coli, Proteus mirabilis andEnterobacter. Cefamandole, the weakest of the compounds tested, was more active than cefoxitin only againstE. coli HR 756 proved to be the most effective cephalosporin derivative in vitro; it exhibited antibacterial activity againstStreptococcus faecalis andPseudomonas aeruginosa. All compounds showed equally high activity againstStaphylococcus aureus. Sixteen patients with chronic infections of the upper urinary tract (8), osteomyelitis (4), soft tissue infections (3) and pneumonia (1) were treated with cefoxitin administered intravenously in dosages ranging from 3 g/die (urinary tract infections) to 12 g/die (soft tissue infections) for a period of 2\u20134 weeks. With the exception of two cases the infection was eliminated with cefoxitin. One patient developed a superinfection withP. aeruginosa. One patient with purulent coxitis caused byProvidencia andPseudomonas aeruginosa did not respond to cefoxitin in a daily dose of 12 g. Side-effects observed consisted of allergic exanthema in one patient, and headache and dizziness after rapid intravenous infusion in another patient. No signs of hematological or nephrological toxicity were observed. Local tolerance was good.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01639474", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1016707", 
        "issn": [
          "0300-8126", 
          "1439-0973"
        ], 
        "name": "Infection", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "HR 756", 
      "soft tissue infections", 
      "upper urinary tract", 
      "rapid intravenous infusion", 
      "andPseudomonas aeruginosa", 
      "allergic exanthema", 
      "daily dose", 
      "tissue infections", 
      "intravenous infusion", 
      "chronic infection", 
      "urinary tract", 
      "local tolerance", 
      "patients", 
      "clinical isolates", 
      "cefoxitin", 
      "cephalosporin derivative", 
      "againstStaphylococcus aureus", 
      "infection", 
      "cefamandole", 
      "agar diffusion technique", 
      "cefuroxime", 
      "coxitis", 
      "dizziness", 
      "osteomyelitis", 
      "pneumonia", 
      "exanthema", 
      "headache", 
      "infusion", 
      "aeruginosa", 
      "dose", 
      "cephalosporins", 
      "cephalothin", 
      "tract", 
      "weeks", 
      "diffusion technique", 
      "vitro", 
      "signs", 
      "dosage", 
      "toxicity", 
      "aureus", 
      "isolates", 
      "period", 
      "cases", 
      "tolerance", 
      "exception", 
      "spp", 
      "compounds", 
      "coli", 
      "technique", 
      "derivatives", 
      "withP.", 
      "die", 
      "standardized agar diffusion technique", 
      "indolpositiveProteus spp", 
      "good activity againstEscherichia coli", 
      "activity againstEscherichia coli", 
      "againstEscherichia coli", 
      "Proteus mirabilis andEnterobacter", 
      "mirabilis andEnterobacter", 
      "andEnterobacter", 
      "coli HR 756", 
      "effective cephalosporin derivative", 
      "antibacterial activity againstStreptococcus faecalis andPseudomonas aeruginosa", 
      "activity againstStreptococcus faecalis andPseudomonas aeruginosa", 
      "againstStreptococcus faecalis andPseudomonas aeruginosa", 
      "faecalis andPseudomonas aeruginosa", 
      "high activity againstStaphylococcus aureus", 
      "activity againstStaphylococcus aureus", 
      "superinfection withP.", 
      "purulent coxitis", 
      "byProvidencia andPseudomonas aeruginosa", 
      "nephrological toxicity", 
      "Mikrobiologische und klinische Erfahrungen mit Cefoxitin", 
      "und klinische Erfahrungen mit Cefoxitin", 
      "klinische Erfahrungen mit Cefoxitin", 
      "Erfahrungen mit Cefoxitin", 
      "mit Cefoxitin"
    ], 
    "name": "Mikrobiologische und klinische Erfahrungen mit Cefoxitin", 
    "pagination": "s99-s102", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046693138"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01639474"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01639474", 
      "https://app.dimensions.ai/details/publication/pub.1046693138"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T17:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_130.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01639474"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01639474'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01639474'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01639474'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01639474'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      22 PREDICATES      104 URIs      94 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01639474 schema:about anzsrc-for:11
2 anzsrc-for:1108
3 schema:author N88121582161343079fee25799560047a
4 schema:citation sg:pub.10.1007/bf01639103
5 sg:pub.10.1007/bf01640793
6 schema:datePublished 1979-01
7 schema:datePublishedReg 1979-01-01
8 schema:description Two hundred and ninety-two clinical isolates resistant to cephalothin were tested against cefamandole, cefoxitin, cefuroxime and HR 756 by the standardized agar diffusion technique. Compared to other cephalosporins tested, cefoxitin was highly active against indolpositiveProteus spp. andSerratia marcescens. Cefuroxime showed good activity againstEscherichia coli, Proteus mirabilis andEnterobacter. Cefamandole, the weakest of the compounds tested, was more active than cefoxitin only againstE. coli HR 756 proved to be the most effective cephalosporin derivative in vitro; it exhibited antibacterial activity againstStreptococcus faecalis andPseudomonas aeruginosa. All compounds showed equally high activity againstStaphylococcus aureus. Sixteen patients with chronic infections of the upper urinary tract (8), osteomyelitis (4), soft tissue infections (3) and pneumonia (1) were treated with cefoxitin administered intravenously in dosages ranging from 3 g/die (urinary tract infections) to 12 g/die (soft tissue infections) for a period of 2–4 weeks. With the exception of two cases the infection was eliminated with cefoxitin. One patient developed a superinfection withP. aeruginosa. One patient with purulent coxitis caused byProvidencia andPseudomonas aeruginosa did not respond to cefoxitin in a daily dose of 12 g. Side-effects observed consisted of allergic exanthema in one patient, and headache and dizziness after rapid intravenous infusion in another patient. No signs of hematological or nephrological toxicity were observed. Local tolerance was good.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf N7c6e3fc9ea0a4f85b304454b04589ed5
13 N9b21e257df8740fb9c0991b6b0d382fc
14 sg:journal.1016707
15 schema:keywords Erfahrungen mit Cefoxitin
16 HR 756
17 Mikrobiologische und klinische Erfahrungen mit Cefoxitin
18 Proteus mirabilis andEnterobacter
19 activity againstEscherichia coli
20 activity againstStaphylococcus aureus
21 activity againstStreptococcus faecalis andPseudomonas aeruginosa
22 aeruginosa
23 againstEscherichia coli
24 againstStaphylococcus aureus
25 againstStreptococcus faecalis andPseudomonas aeruginosa
26 agar diffusion technique
27 allergic exanthema
28 andEnterobacter
29 andPseudomonas aeruginosa
30 antibacterial activity againstStreptococcus faecalis andPseudomonas aeruginosa
31 aureus
32 byProvidencia andPseudomonas aeruginosa
33 cases
34 cefamandole
35 cefoxitin
36 cefuroxime
37 cephalosporin derivative
38 cephalosporins
39 cephalothin
40 chronic infection
41 clinical isolates
42 coli
43 coli HR 756
44 compounds
45 coxitis
46 daily dose
47 derivatives
48 die
49 diffusion technique
50 dizziness
51 dosage
52 dose
53 effective cephalosporin derivative
54 exanthema
55 exception
56 faecalis andPseudomonas aeruginosa
57 good activity againstEscherichia coli
58 headache
59 high activity againstStaphylococcus aureus
60 indolpositiveProteus spp
61 infection
62 infusion
63 intravenous infusion
64 isolates
65 klinische Erfahrungen mit Cefoxitin
66 local tolerance
67 mirabilis andEnterobacter
68 mit Cefoxitin
69 nephrological toxicity
70 osteomyelitis
71 patients
72 period
73 pneumonia
74 purulent coxitis
75 rapid intravenous infusion
76 signs
77 soft tissue infections
78 spp
79 standardized agar diffusion technique
80 superinfection withP.
81 technique
82 tissue infections
83 tolerance
84 toxicity
85 tract
86 und klinische Erfahrungen mit Cefoxitin
87 upper urinary tract
88 urinary tract
89 vitro
90 weeks
91 withP.
92 schema:name Mikrobiologische und klinische Erfahrungen mit Cefoxitin
93 schema:pagination s99-s102
94 schema:productId N10a53f2ff14642cfa6b66c22a2ecc323
95 N901aa4af73c54a4bba95e32168dbebd8
96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046693138
97 https://doi.org/10.1007/bf01639474
98 schema:sdDatePublished 2021-11-01T17:54
99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
100 schema:sdPublisher N7efd2ca1c0f34fbf9e63c12f5bd840af
101 schema:url https://doi.org/10.1007/bf01639474
102 sgo:license sg:explorer/license/
103 sgo:sdDataset articles
104 rdf:type schema:ScholarlyArticle
105 N10a53f2ff14642cfa6b66c22a2ecc323 schema:name dimensions_id
106 schema:value pub.1046693138
107 rdf:type schema:PropertyValue
108 N7c6e3fc9ea0a4f85b304454b04589ed5 schema:volumeNumber 7
109 rdf:type schema:PublicationVolume
110 N7efd2ca1c0f34fbf9e63c12f5bd840af schema:name Springer Nature - SN SciGraph project
111 rdf:type schema:Organization
112 N88121582161343079fee25799560047a rdf:first sg:person.013723243562.29
113 rdf:rest Nd3eed1fc3bf043f38f9f72c723d6badd
114 N901aa4af73c54a4bba95e32168dbebd8 schema:name doi
115 schema:value 10.1007/bf01639474
116 rdf:type schema:PropertyValue
117 N9b21e257df8740fb9c0991b6b0d382fc schema:issueNumber Suppl 1
118 rdf:type schema:PublicationIssue
119 Nd3eed1fc3bf043f38f9f72c723d6badd rdf:first sg:person.014412360064.45
120 rdf:rest Nf1c65b8b2b9a47b8b49db1251124fffc
121 Nf1c65b8b2b9a47b8b49db1251124fffc rdf:first sg:person.016047012041.22
122 rdf:rest rdf:nil
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical Microbiology
128 rdf:type schema:DefinedTerm
129 sg:journal.1016707 schema:issn 0300-8126
130 1439-0973
131 schema:name Infection
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:person.013723243562.29 schema:affiliation grid-institutes:None
135 schema:familyName Graninger
136 schema:givenName W.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013723243562.29
138 rdf:type schema:Person
139 sg:person.014412360064.45 schema:affiliation grid-institutes:None
140 schema:familyName Breyer
141 schema:givenName S.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014412360064.45
143 rdf:type schema:Person
144 sg:person.016047012041.22 schema:affiliation grid-institutes:None
145 schema:familyName Pichler
146 schema:givenName H.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016047012041.22
148 rdf:type schema:Person
149 sg:pub.10.1007/bf01639103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030419629
150 https://doi.org/10.1007/bf01639103
151 rdf:type schema:CreativeWork
152 sg:pub.10.1007/bf01640793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033338319
153 https://doi.org/10.1007/bf01640793
154 rdf:type schema:CreativeWork
155 grid-institutes:None schema:alternateName Universitätsklinik für Chemotherapie, Lazarettgasse 14, A-1090, Wien, österreich
156 schema:name Universitätsklinik für Chemotherapie, Lazarettgasse 14, A-1090, Wien, österreich
157 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...